# US 2010/0063046 A1 · Tetracyclic imidazole analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063046 A1
- Document ID: US20100063046A1
- Status: Published application
- Kind: A1
- Application number: 12/301,090
- Filed: 2007-05-17
- Published: 2010-03-11
- Earliest claimed: 2006-05-17
- Inventors: Jeffrey P. Whitten; Michael Schwaebe
- Web page: https://patentgrep.com/patent/US20100063046A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides tetracyclic imidazole analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing these compounds, and methods of using the same.

## Claims

### Claim 1

A compound of formula (1) or (2) or (3),
wherein each A, V, B, and X that is present is independently selected from H, halo, azido, CN, CF3, CONR1R2, R2, CH2R2, SR2, OR2C(═O)R2, and NR1R2, wherein in NR1R2, R1 and R2 can optionally cyclize to form an optionally substituted azacyclic group; or
wherein A and X, or A and V, or X and B may form a carbocyclic ring, heterocyclic ring, aryl or heteroaryl ring, each of which may be optionally substituted with one or two R3 groups and/or may be fused with an additional ring;
wherein in L-NR1R2, R1 and R2 taken together may form an optionally substituted azacyclic group, or R1 or R2 taken together with at least a portion of L may form an optionally substituted heterocyclic ring;
each Z is independently CH, CR3 or N;
each Z1, Z2, Z3, and Z4 is independently C or N, provided no two of them represent adjacent nitrogen atoms;
T is O, S(O)m or NR4;
each R1 is H or a C1-10 alkyl or C2-10 alkenyl group that can be substituted with one or more substituents selected from halo, ═O, OR2, NR22, S(O)mR2, COOR2, and CONR22;
each m is independently 0-2;
each n is independently 0-4;
each R2 is independently H or an optionally substituted C1-10 alkyl or optionally substituted C2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S in place of carbon atoms, and optionally including a carbocyclic or heterocyclic ring; or R2 is an optionally substituted carbocyclic, heterocyclic, 6-10 membered aryl or 5-14 membered heteroaryl ring containing one or more N, O or S;
each R3 is independently an optionally substituted group selected from C1-6 alkyl, C6-10 aryl, and C5-12 heteroaryl, or R3 is selected from halo, nitro, OR′, SR′, SO2R′, NR′2, CN, CF3, COOR′, and CONR′2, wherein each R′ is independently H or C1-6 alkyl and can optionally include one N, O or S in place of a carbon atom, or R3 can be L-NR1R2 or CON(R′)-L-NR1R2, wherein in NR1R2, R1 and R2 can optionally cyclize to form an optionally substituted azacyclic group;
each R4 is H or a C1-10 alkyl or C2-10 alkenyl group that can be substituted with one or more substituents selected from halo, ═O, OR2, NR22, S(O)mR2, COOR2, and CONR22;
each L is a divalent hydrocarbon linker having up to ten atoms counted along the shortest path between the two open valence, which linker may include one or two heteroatoms and may be substituted by one or more groups selected from halo, ═O, C1-6 alkyl, OR′, SR′, SO2R′, NR′2, CN, CF3, COOR′, and CONR′2, wherein each R′ is independently H or C1-6 alkyl;
each W represents an optionally substituted aryl or heteroaryl ring, which may be a monocyclic group with 5-6 ring atoms, or may be a 5-6 membered ring that is fused with or bonded to one or more additional aryl, heterocyclic, or heteroaryl rings; and
each R5 is a substituent at any position on W, and is selected from H, halo, CN, CF3, OR2, NR1R2, and C1-6 alkyl and C2-6 alkenyl, each optionally substituted by one or more substituents selected from halo, ═O, OR2, S(O)mR2, and NR1R2, wherein in NR1R2, R1 and R2 can optionally cyclize to form an optionally substituted azacyclic group; or R5 can be an inorganic substituent; or two adjacent R5 may be linked to form a 5-6 membered substituted or unsubstituted carbocyclic or heterocyclic ring, optionally fused to an additional substituted or unsubstituted carbocyclic or heterocyclic ring;
or a pharmaceutically acceptable salt thereof.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein Z1 is N.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Z2 is C and X is an optionally substituted azacyclic group.

### Claim 7 (depends on 1)

The compound of claim 1, wherein, in L-NR1R2 shown in the formula, L is (CH2)2-4 and NR1R2 represents an optionally substituted azacyclic group, or -L-NR1R2 shown in the formula represents a group of formula (4):
wherein R1 and R2 are as defined in claim 1, and the substituents R1, if present, and the attachment point for the alkylene linker —(CH2)1-3— can be at any position on the ring other than the nitrogen atom.

### Claim 8 (depends on 1)

The compound of claim 1, which is a compound of formula (1) wherein W represents an optionally substituted phenyl ring.

### Claim 9 (depends on 1)

The compound of claim 1, wherein three of Z1-Z4 represent C and one of Z1-Z4 represents N.

### Claim 10 (depends on 1)

The compound of claim 1, wherein at least one of V, A, B, and X comprises an azacyclic group.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Z1 is N, Z2-Z4 each represent C, and X represents NR1R2, or X comprises an azacyclic group.

### Claim 12 (depends on 11)

The compound of claim 11, wherein L is (CH2)2-4.

### Claim 13 (depends on 1)

The compound of claim 1, wherein W in any compound having formula (1), (2), or (3) is selected from the group consisting of:
wherein each Q, Q1, Q2, and Q3 is independently CR3 or N;
each Y is independently O, CR12, C═O or NR1; and
n, R1, R3 and R5 are as defined above.

### Claim 14 (depends on 13)

The compound of claim 13, which is of the formula (1a), (2a), or (3a).

### Claim 15 (depends on 3)

The compound of claim 3, wherein T is NR4.

### Claim 16 (depends on 1)

The compound of claim 1, which is a compound of formula (2) or formula (3), wherein Z is CH or N, and L is (CH2)2-4.

### Claim 17 (depends on 16)

The compound of claim 16, wherein Z1 is N, Z2-Z4 each represent C, and X represents NR1R2.

### Claim 18 (depends on 17)

The compound of claim 17, wherein W represents an optionally substituted phenyl ring.

### Claim 19 (depends on 1)

The compound of claim 1, wherein L in L-NR1R2 represents (CH2)3, and NR1R2 mL-NR1R2 represents an azacyclic group.

### Claim 20 (depends on 10)

The compound of claim 10, wherein L in L-NR1R2 represents (CH2)3, and NR1R2 in L-NR1R2 represents an azacyclic group.

### Claim 21 (depends on 20)

The compound of claim 20, wherein W represents an optionally substituted phenyl ring.

### Claim 22 (depends on 1)

A method to treat a proliferative disorder or a bacterial infection, which method comprises administering to a subject in need of such treatment, an effective amount of a compound according to claim 1.

### Claim at position 21

23-26. (canceled)

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable excipient.

### Claim at position 23

28-29. (canceled)

### Claim 30 (depends on 1)

A method to treat a condition associated with overexpression of an oncogene, said method comprising administering to a cell in an in vitro or in vivo environment, an effective amount of a compound according to claim 1.

### Claim 31 (depends on 1)

A method to identify a molecule that modulates protein kinase activity, said method comprising screening a compound according to claim 1, or a library of compounds according to claim 1, to identify a compound having an effect on the activity of a protein kinase.

### Claim 32

(canceled)
